Clinical trial
Vyxeos for Induction of Newly Diagnosed Low- or Intermediate-risk AML Patients, Age 18-70. A Pilot Study
NCT05599360 is registered in ClinicalTrials.gov with Shaare Zedek Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Vyxeos for Induction of Newly Diagnosed Low- or Intermediate-risk AML Patients, Age 18-70. A Pilot Study
- Lead sponsor
- Shaare Zedek Medical Center
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- August 7, 2022
- Completion date
- September 7, 2028
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.